etoposide IV

P2, N=108, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

P1, N=24, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting | N=48 --> 24 | Trial primary completion date: Sep 2025 --> Sep 2027

A key management issue was the postoperative intensity of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. The patient remains disease-free on follow-up. This case highlights the following two practical lessons: unusual ovarian germ cell tumors may remain unclassifiable despite integrated pathology, and adjuvant treatment decisions in stage I disease may depend not only on stage but also on staging adequacy and biologic uncertainty.

E6AP-mediated p53 degradation was severely impaired in the presence of the ATM inhibitor KU-55933, indicating that HBx-induced p53 phosphorylation plays a critical role in this process. Additionally, E6AP could target p53 phosphorylated by DNA-damaging agents like etoposide in the absence of HBx...Ser-15 phosphorylation was pivotal, as E6AP could degrade p53 S15D (phosphomimetic mutant) but failed to act on p53 S15A (a non-phosphorylatable mutant). These findings suggest that HBx-induced p53 phosphorylation enhances E6AP-mediated degradation while concurrently inhibiting MDM2-mediated pathways, thereby fine-tuning p53 levels to support cell survival, viral replication and potentially carcinogenesis during HBV infection in human hepatocytes.

The SCLC component dictated adjuvant cisplatin-etoposide regardless of the accompanying adenocarcinoma histology. This case report exemplifies the importance of integrated histologic and molecular evaluation, and the need to recognize potentially actionable mutations in combined SCLC. Comprehensive profiling not only clarifies clonal relationships and may guide therapeutic strategies, including in the context of recurrence or combined presentations.

P2, N=24, Recruiting, University of California, Davis | Trial primary completion date: Feb 2026 --> Oct 2026

P2, N=174, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2028 --> Feb 2027

P3, N=660, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Aug 2026 --> Feb 2028

Both in vitro and in vivo experiments have validated the therapeutic efficacy and molecular mechanisms of IL-11-neutralizing antibodies in pulmonary fibrosis, offering promising insights for future anti-fibrotic drug development. Abbreviations: IL-11, Interleukin-11; IPF, Idiopathic pulmonary fibrosis; TGF-β, Transforming growth factor-β; NOX4, NADPH oxidase-4; SASP, Senescence-associated secretory phenotype; ECM, Extracellular matrix; α-SMA, α-smooth muscle actin; STAT3, Signal transducer and activator of transcription 3; ERK, Extracellular regulated protein kinases; AKT, Protein kinase B; BLM, Bleomycin; WT, Wild-type; KO, Knockout; qRT-PCR, Quantitative real-time polymerase chain reaction; WB, Western blot; hAb, Humanized antibody; mAb, Monoclonal antibody; FVC, Forced vital capacity; CTGF, Connective tissue growth factor; PDGFR-α, Platelet-derived growth factor receptor-α; TNF-α, Tumor necrosis factor-α; Nrf2, NFE2-related factor 2; EMT, Epithelial-mesenchymal transition; HE, Hematoxylin and eosin; PVDF, Polyvinylidene fluoride; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; siRNA, Small interfering RNA; IL-6, Interleukin-6; MEK, Mitogen-Activated Protein Kinase Kinase; TIME, TGF-β1/IL-11/MEK/ERK; HRP, Horseradish Peroxidase; MLG, Mouse lung fibroblast cell line MLg; NCBI, National Center for Biotechnology Information; Bcl2, BCL2 apoptosis regulator; Bax, BCL2 Associated X, apoptosis regulator; MSC, Mesenchymal Stem Cell; RSK, p90 Ribosomal S6 Kinase; KD, Dissociation Constant; Nin, Nintedanib; CTL, Control; Eto, Etoposide; SA-β-Gal, Senescence-Associated β-Galactosidase.

Systemic chemotherapy with vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide was initiated, resulting in tumor shrinkage. To the best of our knowledge, this is the first reported case of BCS treated with CIRT. This case demonstrates that CIRT can achieve durable local control and suggests that it may represent a promising treatment option for BCS when surgical resection is challenging.

Synergism with doxorubicin (DOX) and other chemotherapeutic agents was quantified by combination index (CI) analysis using the Chou-Talalay method and spheroid culture assays...AAP similarly synergized with daunorubicin but not with etoposide or cytarabine, suggesting selectivity for ROS-inducing anthracyclines. These findings establish AMF-derived peptides as promising human-origin chemosensitizers capable of overcoming multidrug resistance in HMs through multi-targeted mechanisms. The ability to reduce anthracycline dosing while maintaining efficacy offers potential for minimizing cardiotoxicity and other dose-limiting adverse effects, warranting further preclinical development toward clinical translation.

Durvalumab plus etoposide-platinum demonstrated a modest treatment response in neuroendocrine-transformed EGFR-mutated NSCLC. AEs were concordant with the known safety profiles of the combination, and no new safety signals were observed.